Jin Rong Jie·2026-02-05 08:44Core Viewpoint - The announcement indicates that the subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd. of Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of SHR-1894 injection, which is expected to play a role in treating atopic dermatitis by protecting the skin barrier and inhibiting inflammation [1] Group 1: Product Development - SHR-1894 injection is a self-developed therapeutic biological product by the company [1] - The clinical trial for SHR-1894 injection will commence shortly following the approval [1] - The total research and development investment for the SHR-1894 injection project has reached approximately 40.1 million yuan [1] Group 2: Market Context - Currently, there are no similar drugs approved for market release domestically or internationally [1]